@incollection{discovery1503787,
           title = {Gefitinib},
            note = {This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.},
       publisher = {nova science publishers},
          number = {22},
            year = {2016},
          editor = {E Una-Cidon},
       booktitle = {The Easy Book of Cancer Pharmacology},
           month = {May},
          author = {Una-Cidon, E and Adeleke, S and Masters, B and Wood, V},
        abstract = {Gefitinib is a small molecule that specifically inhibits the tyrosine kinase (TK) activity of the epidermal growth factor receptor (EGFR) type 1 by interfering with the adenosine triphosphate (ATP) binding site. About 10\% of patient with non-small cell lung cancer (NSCLC) in the US and about 35\% in East Asia have EGFR mutations. [1] Hence gefitinib and the other EGFR inhibitor erlotinib are inevitably important in treatment of NSCLC, of the adenocarcinoma variant with the above mutation.},
             url = {https://novapublishers.com/shop/the-easy-book-of-cancer-pharmacology/},
        keywords = {Targeted agent, personalised medicine, precision medicine}
}